Skip to main navigation
Top Links - Left
BioNTech.com
Newsroom
Investors
Healthcare Professionals
English
Language switcher (Content)
English
German
Top Links - Right
Connect
Main Navigation
BioNTech.com
News
Events & Presentations
Financials
Financials
SEC Filings
Annual Reports
Quarterly Reports
Financial Calendar
Corporate Governance
Corporate Governance
Overview
Transparency
ESG
Stock Info
Stock Info
Stock Quote & Chart
Analyst Coverage
Shareholder Fraud Warning
Share Repurchase Program
Dividend Information
Investor FAQs
Annual General Meeting
Annual General Meeting
Annual General Meeting 2024
Annual General Meeting Archive
Contact Us
Newsroom
Investors
Healthcare Professionals
Breadcrumb
Investors
Search
Search
Filter by content type
(-)
News
(42)
Filter by content year
2024
(2)
2023
(2)
2021
(19)
2020
(19)
Filter by form group
Filter by category
All
(42)
(-)
Other
(42)
(-)
Science
(42)
Collaborators
(34)
Clinical
(24)
Events
(2)
Filter by category
Search
News
Pfizer-BioNTech-COVID-19-Impfstoff induziert im Zellmodell Antikörper, die Pseudoviren mit dem Spike-Protein der U.K.-SARS-CoV-2-Variante neutralisieren
News
Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture
News
Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies’ Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science
News
Pfizer und BioNTech veröffentlichen präklinische Daten zu COVID-19-Impfstoffprogramm in Nature
News
Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature
News
Pfizer und BioNTech reichen Stabilitätsdaten zur Lagerung des COVID-19-Impfstoffs bei Standard-Gefriertemperaturen bei der U.S.-amerikanischen FDA ein
News
Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer Temperature to the U.S. FDA
News
Pfizer und BioNTech veröffentlichen erste positive Daten zu mRNA-basiertem Hauptimpfstoffkandidaten BNT162b2 gegen COVID-19
News
Pfizer and BioNTech Share Positive Early Data on Lead mRNA Vaccine Candidate BNT162b2 Against COVID-19
News
Pfizer und BioNTech veröffentlichen präklinische Daten zu mRNA-basiertem Impfstoffkandidaten gegen COVID-19
Pagination
Previous page
‹‹
Page 2
Next page
››